Back

GENFIT sees NIS technology sales exceeding $1.5 billion by 2033

Verifying
  • GENFIT highlighted the commercial opportunity for its NIS4® and NIS2+® MASH diagnostic technologies.
  • $1.5 billion is IQVIA’s estimate for potential U.S. peak sales by 2033.
  • GENFIT said Medicare coverage for Labcorp’s NASHnext® test became effective in August 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.